Refractory epilepsy: A progressive, intractable but preventable condition?

Seizure

Volumn 11, Issue 2, 2002, Pages 77-84

  Kwan, Patrick ^a   Brodie, Martin J ^b  

^a UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antiepileptic drugs; Drug resistance; Epilepsy surgery; Prevention; Refractory epilepsy; Seizures

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; GLUTAMATE DECARBOXYLASE ANTIBODY; GLUTAMATE RECEPTOR; GLYCOPROTEIN P; ION CHANNEL; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN; NEUROTRANSMITTER RECEPTOR; SODIUM CHANNEL BLOCKING AGENT; VALPROIC ACID;

ARTICLE; AUTOIMMUNITY; BEHAVIOR DISORDER; BIOCHEMISTRY; BRAIN SURGERY; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC FOCUS; HUMAN; INTRACTABLE EPILEPSY; LIFESTYLE; NERVE CELL; NEUROBIOLOGY; NEUROPATHOLOGY; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; RECURRENT DISEASE; REFRACTORY PERIOD; SEIZURE; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036265042     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.2002.0593     Document Type: Article

References (95)

1. Commission on European Affairs: Appropriate standards of epilepsy care across Europe
2. Epidemiology of the epilepsies
3. Epilepsy in elderly people
4. Remission of epilepsy: Results from the national general practice study of epilepsy
5. Early identification of refractory epilepsy
6. Pharmacoresistance in epilepsy: How should it be defined?
7. Clinical aspects and biological bases of drug-resistant epilepsies
8. Antiepileptic drugs
9. Cognitive side-effects of chronic antiepileptic drug treatment: A review of 25 years of research
10. Neuropsychological effects of epilepsy and antiepileptic drugs
11. Patients with refractory seizures
12. Quality of life for people with epilepsy
13. Long-term prognosis of seizures with onset in childhood
14. Risk factors for sudden unexpected death in epilepsy: A case-control study
15. Emerging insights into the genesis of epilepsy
16. Do seizures beget seizures? An assessment of the clinical relevance in humans
17. Randomised study of antiepileptic drug withdrawal in patients in remission
18. Managing pediatric epilepsy syndromes with new antiepileptic drugs
19. Is the underlying cause of epilepsy a major prognostic factor for recurrence?
20. Assessing risk to benefit ratio in antiepileptic drug therapy
21. Does the cause of localisation-related epilepsy influence response to antiepileptic drug treatment?
22. Pathogenesis of mesial temporal sclerosis
23. Seizure circuits in the hippocampus and associated structures
24. Mesial temporal sclerosis: Pathogenesis and significance
25. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy
26. Molecular neuropathology of human mesial temporal lobe epilepsy
27. Synaptic plasticity in kindling
28. + channel β1 subunit gene SCN1B
29. Idiopathic epilepsies with a monogenic mode of inheritance
30. 2-subunit gene
31. 2-subunit in childhood absence epilepsy and febrile seizures
32. Calcium channelopathies
33. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine
34. Epilepsy: An autoimmune disease?
35. Antibodies to glutamate receptor GluR3 in Rasmussen's encephalitis
36. Cryptogenic partial epilepsies with anti-GM1 antibodies: A new form of immune mediated epilepsy?
37. Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies
38. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy
39. Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: A pilot study
40. MDR1 gene expression in brain of patients with medically intractable epilepsy
41. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at the blood-brain barrier sites
42. The physiological function of drug-transporting P-glycoproteins
43. P-glycoprotein and multidrug resistance (MDR) gene expression in epilepsy
44. Progression in mesial temporal lobe epilepsy
45. Neurochemical and morphological changes associated with human epilepsy
46. Systemic factors and epileptic brain damage. Prolonged seizures in paralyzed, artificially ventilated baboons
47. Long-term structural and functional alterations induced in the hippocampus by kindling: Implications for memory dysfunction and the development of epilepsy
48. Synaptic reorganizations in human and rat hippocampal epilepsy
49. Chronic epileptogenic cellular alterations in the limbic system after status epilepticus
50. Synaptic reorganization in the hippocampus induced by abnormal functional activity
51. Experimental partial epileptogenesis
52. Neuronal loss induced in limbic pathways by kindling: Evidence for induction of hippocampal sclerosis by repeated brief seizures
53. Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic seizures
54. Epileptogenic neurons and circuits
55. Rapid and transient increase in cellular immediate early gene and neuropeptide mRNAs in cortical and limbic areas after amygdaloid kindling seizures in the rat
56. Is epilepsy a progressive disease? The neurobiological consequences of epilepsy
57. Seizure-induced hippocampal damage and chronic epilepsy: A Hebbian theory of epileptogenesis
58. The role of secondary epileptogenesis in human epilepsy
59. Magnetic resonance imaging evidence of hippocampal injury after prolonged febrile convulsions
60. Progressive hippocampal atrophy in chronic intractable temporal lobe epilepsy
61. The spectrum of hippocampal sclerosis: A quantitative magnetic resonance imaging study
62. Recurrent seizures may cause hippocampal damage in temporal lobe epilepsy
63. Neuroimaging evidence of progressive neuronal loss and dysfunction in temporal lobe epilepsy
64. Long-term follow-up after temporal lobe resection for lesions associated with chronic seizures
65. Long term effects of refractory temporal lobe epilepsy on cognitive abilities: A cross sectional study
66. Some aspects of prognosis in the epilepsies: A review
67. A controlled trial of diazepam administered during febrile illnesses to prevent recurrence of febrile seizures
68. A randomized double-blind study of phenytoin for the prevention of post-traumatic seizures
69. Etiologic factors for unitemporal vs bitemporal epileptiform discharges
70. Epilepsy after the first drug fails: Substitution or add-on?
71. The timing of surgical intervention for mesial temporal lobe epilepsy: A plan for a randomised clinical trial
72. Basic mechanisms of epilepsy: Targets for therapeutic intervention
73. Mechanisms of epilepsies
74. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy
75. Surgery for seizures
76. Lamotrigine substitution study: Evidence for synergism with sodium valproate?
77. Monotherapy versus polytherapy in epilepsy. A reappraisal
78. The star systems: Overview and use in determining antiepileptic drug choice
79. Effectiveness of first even antiepileptic drug
80. Selection of antiepileptic drug polytherapy based on mechanisms of action: The evidence reviewed
81. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction
82. Management of epilepsy in adolescents and adults
83. A comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondary generalised tonic-clonic seizures
84. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalised tonic-clonic seizures in adults
85. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy
86. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy
87. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: A randomised comparative monotherapy trial
88. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy
89. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
90. A double-blind controlled trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy
91. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy
92. A double-blind controlled clinical trial of oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy
93. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures
94. Gabapentin versus lamotrigine monotherapy: A double-blind comparison
95. Seizure-freedom on more than one antiepileptic drug: A snapshot